These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 17241685)

  • 1. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium.
    Gervelas C; Serandour AL; Geiger S; Grillon G; Fritsch P; Taulelle C; Le Gall B; Benech H; Deverre JR; Fattal E; Tsapis N
    J Control Release; 2007 Mar; 118(1):78-86. PubMed ID: 17241685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential decorporation of americium by pulmonary administration of DTPA dry powder after inhalation of aged PuO(2) containing americium in rats.
    Grémy O; Tsapis N; Chau Q; Renault D; Abram MC; Van der Meeren A
    Radiat Res; 2010 Nov; 174(5):637-44. PubMed ID: 20726717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decorporation of plutonium by pulmonary administration of Ca-DTPA dry powder: a study in rat after lung contamination with different plutonium forms.
    Sérandour AL; Tsapis N; Gervelas C; Grillon G; Fréchou M; Deverre JR; Bénech H; Fattal E; Fritsch P; Poncy JL
    Radiat Prot Dosimetry; 2007; 127(1-4):472-6. PubMed ID: 17562654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decorporation approach following rat lung contamination with a moderately soluble compound of plutonium using local and systemic Ca-DTPA combined chelation.
    Grémy O; Tsapis N; Bruel S; Renault D; Van der Meeren A
    Radiat Res; 2012 Sep; 178(3):217-23. PubMed ID: 22799632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CONRAD approach to biokinetic modeling of DTPA decorporation therapy.
    Breustedt B; Blanchardon E; Bérard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
    Health Phys; 2010 Oct; 99(4):547-52. PubMed ID: 20838097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplified structure of a new model to describe urinary excretion of plutonium after systemic, liver or pulmonary contamination of rats associated with Ca-DTPA treatments.
    Fritsch P; Sérandour AL; Grémy O; Phan G; Tsapis N; Abram MC; Renault D; Fattal E; Benech H; Deverre JR; Poncy JL
    Radiat Res; 2009 Jun; 171(6):674-86. PubMed ID: 19580474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of DTPA entrapped in conventional and long-circulating liposomes of different size for plutonium decorporation.
    Phan G; Herbet A; Cholet S; Benech H; Deverre JR; Fattal E
    J Control Release; 2005 Dec; 110(1):177-88. PubMed ID: 16257469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting plutonium decorporation efficacy after intravenous administration of DTPA formulations: Study of pharmacokinetic-pharmacodynamic relationships in rats.
    Phan G; Le Gall B; Deverre JR; Fattal E; Bénech H
    Pharm Res; 2006 Sep; 23(9):2030-5. PubMed ID: 16951998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced decorporation of plutonium by DTPA encapsulated in small PEG-coated liposomes.
    Phan G; Le Gall B; Grillon G; Rouit E; Fouillit M; Benech H; Fattal E; Deverre JR
    Biochimie; 2006 Nov; 88(11):1843-9. PubMed ID: 16860919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo assessment of plutonium speciation and decorporation in blood and target retention tissues after a systemic contamination followed by an early treatment with DTPA.
    Sérandour AL; Grémy O; Fréchou M; Renault D; Poncy JL; Fritsch P
    Radiat Res; 2008 Aug; 170(2):208-15. PubMed ID: 18666819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of a single model to describe plutonium and americium decorporation by DTPA treatments.
    Fritsch P; Sérandour AL; Grémy O; Phan G; Tsapis N; Fattal E; Benech H; Deverre JR; Poncy JL
    Health Phys; 2010 Oct; 99(4):553-9. PubMed ID: 20838098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery.
    Cruz L; Fattal E; Tasso L; Freitas GC; Carregaro AB; Guterres SS; Pohlmann AR; Tsapis N
    J Control Release; 2011 Jun; 152(3):370-5. PubMed ID: 21396412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isotopic and elemental composition of plutonium/americium oxides influence pulmonary and extra-pulmonary distribution after inhalation in rats.
    Van der Meeren A; Grémy O
    Health Phys; 2010 Sep; 99(3):380-7. PubMed ID: 20699701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.
    Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI
    J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of human contamination with plutonium and americium: would orally administered Ca- or Zn-DTPA be effective?
    Taylor DM; Hodgson SA; Stradling N
    Radiat Prot Dosimetry; 2007; 127(1-4):469-71. PubMed ID: 17556346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
    Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
    J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats.
    Bosquillon C; Préat V; Vanbever R
    J Control Release; 2004 Apr; 96(2):233-44. PubMed ID: 15081215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach.
    Breustedt B; Blanchardon E; Berard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
    Radiat Prot Dosimetry; 2009 Feb; 134(1):38-48. PubMed ID: 19351653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats.
    Carvalho SR; Watts AB; Peters JI; Liu S; Hengsawas S; Escotet-Espinoza MS; Williams RO
    Eur J Pharm Biopharm; 2014 Sep; 88(1):136-47. PubMed ID: 24859653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.